ABBV vs GKOS: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

ABBV is the larger of the two ($509.92B market cap): the incumbent the market prices for continued execution (17.79x forward earnings, beta 0.19). GKOS is the smaller challenger ($14.00B), actually pricier on forward earnings (168.96x): more room to run, but more to prove. If you believe in growth, GKOS fits: analysts expect its revenue to rise 29% next year, against 9% for ABBV. If you believe in paying less for profit, ABBV fits: it trades at 17.79x forward earnings, against 168.96x for GKOS.

ABBV vs GKOS: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricABBVGKOSWhat it tells you
Market cap$509.92B$14.00BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E17.79168.96Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.190.68Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range87% of range88% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.

Reading it: ABBV is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how ABBV and GKOS affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABBV and GKOS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABBV and GKOS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does AbbVie (ABBV) do?

AbbVie is a North Chicago-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013. It focuses on discovering and commercializing medicines for immunology, oncology, neuroscience, and aesthetics. Its immunology franchise anchors the business: historically through Humira (adalimumab), and increasingly through Skyrizi (risankizumab) and Rinvoq (upadacitinib), which treat conditions such as plaque psoriasis, Crohn's disease, rheumatoid arthritis, and ulcerative colitis. Oncology contributes through Imbruvica (developed in collaboration with Johnson and Johnson) and Venclexta (in collaboration with Roche), while the 2020 acquisition of Allergan added Botox Therapeutic, Vraylar, and the aesthetics portfolio including Botox Cosmetic and Juvederm. Revenue is generated by selling branded pharmaceuticals at negotiated prices to wholesale distributors, specialty pharmacies, and health systems across more than 175 countries.

Full ABBV guide

What does Glaukos Corporation (GKOS) do?

Glaukos Corporation is a San Clemente, California ophthalmic medical technology and pharmaceutical company focused on glaucoma, corneal disorders, and retinal disease. It pioneered Micro-Invasive Glaucoma Surgery (MIGS) with the iStent family of implants and has expanded into sustained-release drug delivery with iDose TR (a glaucoma implant) and corneal therapies including Photrexa and the newer Epioxa cross-linking treatment for keratoconus. In October 2026 it added a retinal program by licensing RO-104, a tri-specific biologic for retinal diseases, from RevOpsis Therapeutics. The company sells through eye surgeons and clinics in the US and internationally. Growth has been accelerating: Q1 2026 net sales were roughly $150.6 million, up about 41% year over year (iDose TR contributed around $54 million), Q2 2026 net sales reached about $185.6 million, up roughly 50%, and Q3 2026 net sales reached about $211.0 million, up roughly 58%, taking trailing twelve-month revenue to about $690 million.

Full GKOS guide

ABBV vs GKOS: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • ABBV drivers: Skyrizi and Rinvoq replacing Humira faster than expected; Neuroscience becoming a meaningful second growth engine.
  • GKOS drivers: iDose TR ramp; Corneal health and Epioxa.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. For GKOS, glaukos has only one profitable quarter behind it and trades at about 20 times trailing sales and about 169 times forward earnings, so any slowdown in iDose TR or Epioxa adoption could pressure the stock sharply.

ABBV or GKOS: which should you pick?

If the story you believe is ABBV's (Skyrizi and Rinvoq replacing Humira faster than expected), ABBV is the more direct way to own it; if it is GKOS's (iDose TR ramp), GKOS is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABBV and GKOS guides.

ABBV vs GKOS: the full fundamentals

ABBV. The gap between the trailing GAAP P/E (about 50x, inflated by non-cash acquired IPR and D charges on recent deals) and the forward P/E of roughly 17.8x illustrates why analysts and management prefer adjusted metrics: upfront licensing and milestone payments depress reported earnings without reducing cash generation. The trailing multiple has fallen from about 80x in October as a strong Q3 GAAP quarter (about $4.2 billion of net income) replaced weaker ones, while the forward multiple has drifted up with the share price. The 26 covering analysts have a buy consensus and a mean target near $316.

GKOS. Glaukos combines roughly 58% revenue growth with its first small quarterly profit, so it screens as a high-multiple growth medtech, not a value name, with a negative trailing P/E and a forward P/E near 169. After a roughly 149% one-year gain the stock sits just below the average analyst target of about $244. The next report, for the fourth quarter, carries consensus of about $233 million of revenue and $0.47 of EPS.

Headline figures (approximate, November 2026): ABBV shows revenue (ttm) ~$66.0 billion (Q3 2026 ~$17.4B, up ~10% YoY), adjusted eps Q3 2026 $3.82 vs $3.76 estimate; FY2026 consensus ~$13.98; FY2027 consensus ~$16.22, gaap net income (ttm) ~$10.3 billion (GAAP EPS ~$5.82, depressed by acquired IPR and D), margins (ttm) ~74% gross, ~37% operating, ~16% net; GKOS shows revenue (ttm) ~$690M, q3 2026 net sales ~$211.0M (up ~58% YoY), 2026 revenue (analyst consensus) ~$781M; 2027 ~$1.0B, gross margin ~81%.

The bottom line: ABBV vs GKOS

ABBV and GKOS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ABBV and GKOS exposure against your real portfolio. It is not an investment adviser.

Wondering how ABBV or GKOS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about AbbVie

Ask Walnut's AI anything about ABBV and see how it fits what you own.

FAQ

What is the difference between ABBV and GKOS?

+

AbbVie is a North Chicago-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013. Glaukos Corporation is a San Clemente, California ophthalmic medical technology and pharmaceutical company focused on glaucoma, corneal disorders, and retinal disease. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ABBV or GKOS the better stock?

+

Neither is universally better. ABBV is the larger incumbent; GKOS is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ABBV or GKOS?

+

On forward P/E (as of November 2026), ABBV trades at 17.79x and GKOS at 168.96x, so ABBV is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ABBV and GKOS?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ABBV vs GKOS?

+

ABBV: The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. AbbVie also carries a heavy debt load, about $81.3 billion as of September 2026 against about $10.8 billion of cash, a legacy of the Allergan acquisition, constraining financial flexibility if credit markets tighten or a major pipeline bet fails. GAAP earnings are depressed by acquired research charges, so the dividend exceeds trailing GAAP net income (a payout ratio near 117% of trailing GAAP EPS of about $5.82), and it is covered by cash flow rather than reported profit. Integrating acquisitions such as Apogee Therapeutics introduces execution risk, the aesthetics segment (Botox Cosmetic, Juvederm) has shown sensitivity to consumer spending cycles, and after a 26% gain in 2026 the shares trade near their highs, though the mean analyst target has risen to about $316. GKOS: Glaukos has only one profitable quarter behind it and trades at about 20 times trailing sales and about 169 times forward earnings, so any slowdown in iDose TR or Epioxa adoption could pressure the stock sharply. Reimbursement complexity is a recurring watchpoint, including Medicaid Drug Rebate Program impacts that have muted Photrexa and general pricing pressure in glaucoma devices. Competition is intense from Alcon, Sight Sciences, AbbVie, Johnson & Johnson, and others across MIGS and glaucoma drug delivery, and a competitor supply recovery or new launch could erode share. The legacy iStent business has shown flattish trends outside iDose, and international markets face new competitive product trialing. Heavy spending relative to current earnings means execution and continued access to capital both matter. The shares have swung widely, from a 52-week low near $94 to a high near $255, and rose about 32% in the month to November 20, 2026, so the price now sits close to the average analyst target of about $244. The new RO-104 retinal license adds early-stage development risk.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ABBV or GKOS; figures are approximate and dated (as of November 2026). Verify current data before investing.